Registry for Participants With Short Bowel Syndrome

Conditions

Short Bowel Syndrome

Keywords

Short Bowel Syndrome, SBS, teduglutide, Gattex

Brief summary

This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.

Gabriel Gondolesi, Ulrich‐Frank Pape, Joel B. Mason, Johane P. Allard, Loris Pironi et al. (14 authors)

Nutrients2024-08-013 citations

10.3390/nu16152513

62: Long-term safety analysis of teduglutide treatment in adult patients with short bowel syndrome and intestinal failure (SBS-IF): analysis from a prospective, multinational SBS-IF registry

Gabriel Gondolesi, Joel B. Mason, Elisabeth Genestin, Palle Bekker Jeppersen, Francisca Joly et al. (10 authors)

Transplantation2023-06-261 citations

10.1097/01.tp.0000945704.64296.38

Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials

Ulrich‐Frank Pape, Kishore Iyer, Palle Bekker Jeppesen, Marek Kunecki, Loris Pironi et al. (9 authors)

Therapeutic Advances in Gastroenterology2020-01-0150 citations

10.1177/1756284820905766

Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Iyer KR, Kunecki M, Boullata JI, Fujioka K, Joly F, Gabe S, Pape UF, Schneider SM, Virgili Casas MN, Ziegler TR, Li B, Youssef NN, Jeppesen PB.

2016-11-2359 citations

10.1177/0148607116680791

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

No

Inclusion criteria

1. Male and female participants, of any age, with a diagnosis of short bowel syndrome (SBS). 2. Signed informed consent and medical records release by the participant or a legally acceptable representative 3. Participants who have never received teduglutide treatment must be on parenteral nutrition (PN)/intravenous (IV) fluids support for at least 6 months at the time of enrollment.

Exclusion criteria

1. Participants currently participating in a blinded clinical trial or their extension studies. 2. Participants who have never been on PN/IV support. 3. Participants who are currently or previously exposed to any Glucagon-like peptide 2 (GLP-2) analogs other than teduglutide.

Design outcomes

Primary

Measure	Time frame	Description
Occurrence of Colorectal Cancer in Short Bowel Syndrome (SBS) Participants With a Remnant Colon Currently Being Treated With or Ever Having Been Treated With Teduglutide	10 years	Incidence rates of colorectal cancer in participants will be calculated by dividing the number of incident colorectal cancer cases by the total number of person-years observed since beginning treatment with teduglutide.

Secondary

Measure	Time frame	Description
Occurrence of Other Malignancy	10 years	Incidence rates of other malignancies will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Benign Neoplasia of the Gastrointestinal (GI) tract, Hepatobiliary System, and Pancreas in Participants	10 years	Incidence rates of benign neoplasia of the GI tract, hepatobiliary system, and pancreas will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Intestinal Obstruction	10 years	Incidence rates of intestinal obstruction will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Pancreatic and Biliary Disease	10 years	Incidence rates of pancreatic and biliary disease will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Heart Failure and Other Manifestations of Volume Overload	10 years	Incidence rates of heart failure and other manifestations of volume overload will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Allergic/Hypersensitivity Reaction to Teduglutide	10 years	Incidence rates of allergic/hypersensitivity reactions to teduglutide will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Occurrence of Colorectal Polyps	10 years	Incidence rates of colorectal polyps will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide.
Actual Volume Change in Parenteral Support (PS)	10 years	PS will be measured by parenteral treatment volume (liters/week) and days (days/week) that occurred in the 7 days prior to the visit.
Percentage Volume Change in Parenteral Support (PS)	10 years	PS will be measured by parenteral treatment volume (liters/week) and days (days/week) that occurred in the 7 days prior to the visit.
Actual Change in the Number of Days per Week on Parenteral Support (PS)	10 years	PS will be measured by parenteral treatment volume (liters/week) and days (days/week) that occurred in the 7 days prior to the visit.
Percentage Change in the Number of Days per Week on Parenteral Support (PS)	10 years	PS will be measured by parenteral treatment volume (liters/week) and days (days/week) that occurred in the 7 days prior to the visit.
Percent of Participants Weaning From Parental Support (PS)	10 years	PS will be measured by parenteral treatment volume (liters/week) and days (days/week) that occurred in the 7 days prior to the visit.
Occurrence of Other Adverse Events (AEs) Potentially Related to Treatment with Teduglutide	10 years	Incidence rates of other AEs will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide. Incidence rates of other AEs will be calculated by dividing the number of incident cases by the total number of person-years observed since beginning treatment with teduglutide. An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product (ICH Guidance E2A 1995). This includes an exacerbation of a pre-existing condition.

Countries

United States

Outcome results